You are here
- Home
- Drug Products
- All Drug Products
An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg
- Disease
- rheumatoid arthritis
- Drug Name
- Fostamatinib Disodium
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- I
- Start Date
- Nov 29, 2010
- Study Name
- D4300C00009
- Study Id
- D4300C00009
- ClinicalTrials.gov ID
- NCT01245790
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
